Literature DB >> 28848059

CTCF deletion syndrome: clinical features and epigenetic delineation.

Ikumi Hori1, Rie Kawamura2, Kazuhiko Nakabayashi3, Hidetaka Watanabe4, Ken Higashimoto4, Junko Tomikawa3, Daisuke Ieda1, Kei Ohashi1, Yutaka Negishi1, Ayako Hattori1, Yoshitsugu Sugio5, Keiko Wakui2, Kenichiro Hata3, Hidenobu Soejima4, Kenji Kurosawa6, Shinji Saitoh1.   

Abstract

BACKGROUND: Heterozygous mutations in CTCF have been reported in patients with distinct clinical features including intellectual disability. However, the precise pathomechanism underlying the phenotype remains to be uncovered, partly because of the diverse function of CTCF. Here we describe extensive clinical and genetic investigation for two patients with a microdeletion encompassing CTCF.
METHODS: We performed genetic examination including comprehensive investigation of X chromosome inactivation and DNA methylation profiling at imprinted loci and genome-wide.
RESULTS: Two patients showed comparable clinical features to those in a previous report, indicating that haploinsufficiency of CTCF was the major determinant of the microdeletion syndrome. Despite the haploinsufficiency of CTCF, X chromosome inactivation was normal. DNA methylation at imprinted loci was normal, but hypermethylation at CTCF binding sites was demonstrated, of which PRKCZ and FGFR2 were identified as candidate genes.
CONCLUSIONS: This study confirms that haploinsufficiency of CTCF causes distinct clinical features, and that a microdeletion encompassing CTCF could cause a recognisable CTCF deletion syndrome. Perturbed DNA methylation at CTCF binding sites, not at imprinted loci, may underlie the pathomechanism of the syndrome. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  DNA methylation; X chromosome inactivation; microdeletion

Mesh:

Substances:

Year:  2017        PMID: 28848059     DOI: 10.1136/jmedgenet-2017-104854

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  10 in total

Review 1.  Developing in 3D: the role of CTCF in cell differentiation.

Authors:  Rodrigo G Arzate-Mejía; Félix Recillas-Targa; Victor G Corces
Journal:  Development       Date:  2018-03-22       Impact factor: 6.868

2.  Depletion of CTCF induces craniofacial malformations in mouse embryos.

Authors:  Hyehyun Min; Hyoung-Pyo Kim; Jeong-Oh Shin
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 3.  Regulation of 3D chromatin organization by CTCF.

Authors:  Jian-Feng Xiang; Victor G Corces
Journal:  Curr Opin Genet Dev       Date:  2020-11-28       Impact factor: 5.578

4.  CTCF Expression is Essential for Somatic Cell Viability and Protection Against Cancer.

Authors:  Charles G Bailey; Cynthia Metierre; Yue Feng; Kinsha Baidya; Galina N Filippova; Dmitri I Loukinov; Victor V Lobanenkov; Crystal Semaan; John Ej Rasko
Journal:  Int J Mol Sci       Date:  2018-11-30       Impact factor: 5.923

5.  CTCF variants in 39 individuals with a variable neurodevelopmental disorder broaden the mutational and clinical spectrum.

Authors:  Enrico D H Konrad; Niels Nardini; Almuth Caliebe; Inga Nagel; Dana Young; Gabriella Horvath; Stephanie L Santoro; Christine Shuss; Alban Ziegler; Dominique Bonneau; Marlies Kempers; Rolph Pfundt; Eric Legius; Arjan Bouman; Kyra E Stuurman; Katrin Õunap; Sander Pajusalu; Monica H Wojcik; Georgia Vasileiou; Gwenaël Le Guyader; Hege M Schnelle; Siren Berland; Evelien Zonneveld-Huijssoon; Simone Kersten; Aditi Gupta; Patrick R Blackburn; Marissa S Ellingson; Matthew J Ferber; Radhika Dhamija; Eric W Klee; Meriel McEntagart; Klaske D Lichtenbelt; Amy Kenney; Samantha A Vergano; Rami Abou Jamra; Konrad Platzer; Mary Ella Pierpont; Divya Khattar; Robert J Hopkin; Richard J Martin; Marjolijn C J Jongmans; Vivian Y Chang; Julian A Martinez-Agosto; Outi Kuismin; Mitja I Kurki; Olli Pietiläinen; Aarno Palotie; Timothy J Maarup; Diana S Johnson; Katja Venborg Pedersen; Lone W Laulund; Sally A Lynch; Moira Blyth; Katrina Prescott; Natalie Canham; Rita Ibitoye; Eva H Brilstra; Marwan Shinawi; Emily Fassi; Heinrich Sticht; Anne Gregor; Hilde Van Esch; Christiane Zweier
Journal:  Genet Med       Date:  2019-06-26       Impact factor: 8.822

Review 6.  Clustered Protocadherins Emerge as Novel Susceptibility Loci for Mental Disorders.

Authors:  Zhilian Jia; Qiang Wu
Journal:  Front Neurosci       Date:  2020-11-12       Impact factor: 4.677

7.  Identification and characterization of novel ACD variants: modulation of TPP1 protein level offsets the impact of germline loss-of-function variants on telomere length.

Authors:  Gabrielle Henslee; Christopher L Williams; Pengfei Liu; Alison A Bertuch
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-02-19

Review 8.  Implications of Dosage Deficiencies in CTCF and Cohesin on Genome Organization, Gene Expression, and Human Neurodevelopment.

Authors:  Christopher T Cummings; M Jordan Rowley
Journal:  Genes (Basel)       Date:  2022-03-25       Impact factor: 4.141

9.  Hypermethylation of PRKCZ Regulated by E6 Inhibits Invasion and EMT via Cdc42 in HPV-Related Head and Neck Squamous Cell Carcinoma.

Authors:  Hao-Fan Wang; Jian Jiang; Jia-Shun Wu; Mei Zhang; Xin Pang; Li Dai; Ya-Ling Tang; Xin-Hua Liang
Journal:  Cancers (Basel)       Date:  2022-08-27       Impact factor: 6.575

Review 10.  Crosstalk of Genetic Variants, Allele-Specific DNA Methylation, and Environmental Factors for Complex Disease Risk.

Authors:  Huishan Wang; Dan Lou; Zhibin Wang
Journal:  Front Genet       Date:  2019-01-09       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.